Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts dalbavancin MAA for review

Dec. 24, 2013

EMA accepts filing of MAA for cangrelor

Dec. 24, 2013

Cometriq receives positive CHMP opinion for thyroid carcinoma

Dec. 23, 2013

MultiStem receives orphan drug designation in Europe

Dec. 18, 2013

EMA accepts Fibrocaps MAA for review

Nov. 29, 2013

EMA grants accelerated assessment to faldaprevir

Nov. 27, 2013

Celgene receives positive CHMP opinion for Abraxane in combination with gemcitabine

Nov. 26, 2013

Ariad Pharmaceuticals obtains positive CHMP opinion on the continued use of Iclusig

Nov. 26, 2013

Dimethyl fumarate in Tecfidera qualifies as new active substance in Europe

Nov. 25, 2013

Deltyba obtains European CHMP recommendation upon re-examination

Nov. 25, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...